clinical trial · NCT06963502
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.·phase1·not yet recruiting·n = 762
Advanced Solid TumorsColorectal CancerNon-Small Cell Lung CancerHS-10370HS-20117AdebrelimabCapecitabineOxaliplatinFolinic Acid, Fluorouracil and Oxaliplatin/IrinotecanHS-20093platinum (cisplatin or carboplatin)
brief summary
This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics, Activity and Immunogenicity of HS-10370 in Combination With Other Anti-cancer Therapies in Chinese patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in and Colorectal cancer(CRC) and non-Small cell lung cancer (NSCLC).
started
May 30, 2025
primary completion
Dec 31, 2028
completion
Apr 30, 2030
last updated
May 9, 2025
official title
A Phase Ib Study Evaluating the Safety, Tolerability , Pharmacokinetics，Activity and Immunogenicity of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol